ClinicalTrials.gg
RecruitingNCT06679777SCAPIS2Updated Nov 7, 2024

Swedish CArdioPulmonary bioImage Study 2

An observational study in Cardiovascular Diseases and Lung Diseases, sponsored by Karolinska Institutet. Recruiting at 6 sites in Sweden. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Karolinska Institutet · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30,154
Sex
All
01

Study summary

In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.

In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.

Read the detailed description

The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and lung disease in the general population by identifying novel risk markers. This is also the purpose of SCAPIS 2, which further aims to gain important insights into risk factors and longitudinal development of heart, vascular and lung diseases such as atherosclerosis and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study participants approximately 8-10 years after the baseline examination SCAPIS 1.

The five overall objectives of SCAPIS 2 are:

  1. To determine characteristics related to the natural progression of atherosclerosis over 8-10 years.
  2. To evaluate characteristics related to pathological cardiovascular aging over 8-10 years.
  3. To determine characteristics related to the natural progression of lung function over 8-10 years.
  4. To determine risk factors associated with the progression of coronary atherosclerosis and the development of impaired lung function or structural changes of the lungs.
  5. To compare outcome in individuals who are invited to SCAPIS 2 and those not invited.

SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline examination (SCAPIS 1) study population approximately 8-10 years after their initial participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were drawn from each recruitment area in the Swedish population registry until approximately 30 000 subjects were included. The final number was 30 154 subjects with an even sex and age distribution. The original recruitment process ensured that the study population in SCAPIS 1 was representative for the Swedish population in general.

An invitation letter with brief information about SCAPIS 2 will be sent to randomly selected individuals by mail, including phone number and e-mail address to the study center. The invitation letter will refer to a study webpage where the subjects can indicate if they are interested in participating in SCAPIS 2 and read the subject information in advance (voluntary). The invitation also includes contact information to the study center to be used if the subject prefers to not use the web page or has questions. Subjects that have moved since their participation in SCAPIS 1 will be invited to the same study center as their baseline examination.

The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever possible, all visits should be performed within a period of 4 weeks. Examinations that are common for all sites include:

  • Medical history
  • Anthropometry
  • Clinical chemistry/hematology: Hb, p-Glucose, HbA1c, s-TG, s- Cholesterol, LDL, HDL, creatinine, detailed leukocyte count)
  • Biobank sampling (plasma, serum, whole blood, and urine)
  • Spirometry
  • CO uptake
  • Questionnaires
  • Accelerometry (hip)
  • Electrocardiogram (ECG)
  • Heart rate
  • Blood pressure
  • Computed tomography (CT)

    • Body composition
    • Lung tissue
    • Coronary artery calcium score (CACS)
    • Coronary computed tomography angiography (CCTA)

All subjects will be fasting overnight (at least 8 hours) before the first visit. If a subject has not been fasting overnight, blood sampling should be rescheduled and performed preferably at an extra visit but no later than Visit 2. For subjects with elevated plasma glucose levels, an overnight fasting glucose measurement will be repeated.

Subjects should be instructed to take their regular medication as usual also when fasting. The only medication that should not be taken is medication for diabetes, per oral as well as injections. Subjects with diabetes should be fasting as all other subjects and should bring their medication to take when having breakfast at the clinic. To obtain standardized conditions for the CT examination, subjects are recommended to be fasting for at least 4 hours before intake of a standardized meal. The standardized meal should be consumed 2 hours before the CT scan.

All clinical findings and assessment of risk should be taken care of according to current guidelines and SCAPIS manual.

02

Conditions studied

  • Cardiovascular Diseases
  • Lung Diseases
03

In context

Cardiovascular Diseases

5,025 studies on the registry are indexed under Cardiovascular Diseases; 930 are open to participants now.

This study's planned enrollment of 30,154 is above the median of 600 across 1,524 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,145 studies on the registry; 274 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.

In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participated in SCAPIS 1.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have withdrawn their informed consent during or after SCAPIS 1.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30,154 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Cardiovascular death, non-fatal myocardial infarction or stroke.

    Cardiovascular death, non-fatal myocardial infarction or stroke.

    Time frame: Through study completion, an average of 5 years

Secondary outcomes

  1. Cardiovascular death or non-fatal myocardial infarction

    Cardiovascular death or non-fatal myocardial infarction

    Time frame: Through study completion, an average of 5 years

  2. Cardiovascular death

    Cardiovascular death

    Time frame: Through study completion, an average of 5 years

  3. Myocardial infarction (fatal or non-fatal)

    Myocardial infarction (fatal or non-fatal)

    Time frame: Through study completion, an average of 5 years

  4. Stroke (fatal or non-fatal)

    Stroke (fatal or non-fatal)

    Time frame: Through study completion, an average of 5 years

  5. Death (all-cause)

    Death (all-cause)

    Time frame: Through study completion, an average of 5 years

  6. Unstable angina requiring revascularization

    Unstable angina requiring revascularization

    Time frame: Through study completion, an average of 5 years

  7. Chronic obstructive pulmonary disease (COPD)

    Chronic obstructive pulmonary disease (COPD)

    Time frame: Through study completion, an average of 5 years

  8. Lung cancer

    Lung cancer

    Time frame: Through study completion, an average of 5 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • Bergstrom G, Berglund G, Blomberg A, Brandberg J, Engstrom G, Engvall J, Eriksson M, de Faire U, Flinck A, Hansson MG, Hedblad B, Hjelmgren O, Janson C, Jernberg T, Johnsson A, Johansson L, Lind L, Lofdahl CG, Melander O, Ostgren CJ, Persson A, Persson M, Sandstrom A, Schmidt C, Soderberg S, Sundstrom J, Toren K, Waldenstrom A, Wedel H, Vikgren J, Fagerberg B, Rosengren A. The Swedish CArdioPulmonary BioImage Study: objectives and design. J Intern Med. 2015 Dec;278(6):645-59. doi: 10.1111/joim.12384. Epub 2015 Jun 19. PubMed 26096600 ↗

Related links

Individual participant data

Plan to share: Yes — Individual participant data can be shared if approved the Swedish Ethical Review Authority and authority responsible for personal data

Supporting information: Study protocol, Informed consent form

Time frame: After study completion

Access criteria: Approval from the Swedish Ethical Review Authority and authority responsible for personal data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06679777
Responsible party
Tomas Jernberg (Professor, Karolinska Institutet) — Principal investigator
First posted
Nov 7, 2024
Start date
Jan 15, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 7, 2024

Study contacts

Tomas Jernberg, PhD
Contact
tomas.jernberg@ki.se
+46-70-1671474
Vibeke Sparring, PhD
Contact
vibeke.sparring@hjart-lungfonden.se
+46-70-854 44 89
Carl Johan Östgren, PhD
principal investigator · Linkoeping University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion